Continuous Nanoparticle Manufacturing For Gene Editing Delivery

For genetic diseases, gene editing technologies like CRISPR/Cas9 offer a new way to make precise changes to DNA. However, the success of these therapies relies on how the editing tools are delivered to the cells. Messenger RNA encapsulated in lipid nanoparticles (mRNA-LNPs) has emerged as a preferred method because it protects the RNA molecules, promotes cellular uptake, and allows temporary expression of the editing components. This temporary expression helps reduce the risk of unwanted, off-target genetic activity.

To bring these therapies to the clinic, a reliable and scalable manufacturing process is necessary to produce consistent nanoparticles. Continuous manufacturing can help address this challenge by integrating key steps like particle formation, purification, and monitoring into a single, automated system. Learn how this approach can help streamline the path from laboratory research to large-scale production, potentially accelerating the development of new gene editing therapies.